Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study
NCT ID: NCT06589414
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
171 participants
INTERVENTIONAL
2025-01-08
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
171 patients will be included in the study.
Each patient will be followed for 6 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
NCT03694171
Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours
NCT03328065
the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients
NCT04415190
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
NCT02598219
Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over
NCT03077178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DAMeGe protocol
Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)
A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.
At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.
In addition, patients will be asked to complete a "patient diary" for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)
A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.
At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.
In addition, patients will be asked to complete a "patient diary" for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient with a solid tumour whatever the organ.
3. Patient treated in one of the participating centres as part of a system for announcing the diagnosis of a solid cancer.
4. Patient undergoing cancer treatment in one of the participating centres.
5. Patient with a registered general practitioner in the Occitanie region.
6. Patient affiliated to a French Social Security scheme.
7. Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study.
Exclusion Criteria
2. Patient deprived of liberty or under legal protection (curatorship and guardianship, safeguard of justice).
3. Pregnant or breast-feeding woman.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ligue contre le cancer, France
OTHER
Institut Claudius Regaud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH Auch
Auch, , France
CH Carcassonne
Carcassonne, , France
CHU Larrey
Toulouse, , France
CHU Rangueil
Toulouse, , France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID RCB Number: 2024-A00415-42
Identifier Type: OTHER
Identifier Source: secondary_id
24 GENE 07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.